Home Newsfeeds Oppenheimer Initiates Coverage On D.R. Horton with Perform Rating

Oppenheimer Initiates Coverage On D.R. Horton with Perform Rating

Oppenheimer analyst Tyler Batory initiates coverage on D.R. Horton (NYSE:DHI) with a Perform rating.

byBenzinga Newsdesk

January 19, 2023

1 minute read

Oppenheimer analyst Tyler Batory initiates coverage on D.R. Horton (NYSE:DHI) with a Perform rating.

Neurocrine Biosciences To Present Phase 3 Baseline Characteristics Data From The CAHtalyst Program Of Crinecerfont In CAH, And Data For Modified-Release Hydrocortisone In Primary Adrenal Insufficiency And CAH Studies At ECE 2024

By Benzinga Newsdesk

May 7, 8:38 AM

CAHtalyst™ Pediatric and CAHtalyst™ Adult Baseline Characteristics Data in Congenital Adrenal HyperplasiaPhase 2 (CHAMPAIN) Clinical Study Data for Modified-Release Hydrocortisone

NBIX

New Jersey Division Of Gaming Enforcement Has Closed Its Investigation Of Evolution AB With No Further Action

By Benzinga Newsdesk

February 20, 3:57 AM

Evolution AB has been informed by the New Jersey Division of Gaming Enforcement (NJDGE) that it has conducted an investigation into allegations of misconduct by Evolution AB and that its investigation has been

EVO

News
Rumors

Article From Dec 15 Suggests ‘Apple To Launch AR/VR Headset At WWDC 2023, Leaker Claims’ – BGR

By Benzinga Newsdesk

December 27, 1:04 PM

https://bgr.com/tech/apple-to-launch-ar-vr-headset-at-wwdc-2023-leaker-claims/?taid=63ab24a455e0a20001a88883 Apple has been developing its first mixed reality headset for several years, although rumors about the

AAPL

Mizuho Maintains Buy on Essential Props Realty, Raises Price Target to $25

By Benzinga Newsdesk

December 8, 9:54 AM

Mizuho analyst Haendel St. Juste maintains Essential Props Realty (NYSE:EPRT) with a Buy and raises the price target from $21 to $25.

EPRT

Oppenheimer Initiates Coverage On D.R. Horton with Perform Rating

Related Posts

Neurocrine Biosciences To Present Phase 3 Baseline Characteristics Data From The CAHtalyst Program Of Crinecerfont In CAH, And Data For Modified-Release Hydrocortisone In Primary Adrenal Insufficiency And CAH Studies At ECE 2024

New Jersey Division Of Gaming Enforcement Has Closed Its Investigation Of Evolution AB With No Further Action

Article From Dec 15 Suggests ‘Apple To Launch AR/VR Headset At WWDC 2023, Leaker Claims’ – BGR

Mizuho Maintains Buy on Essential Props Realty, Raises Price Target to $25